Bayesian Capital Management LP purchased a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 22,935 shares of the company’s stock, valued at approximately $177,000.
Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Travere Therapeutics by 10.9% in the third quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock valued at $41,727,000 after buying an additional 460,176 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in Travere Therapeutics by 76.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,018,812 shares of the company’s stock valued at $9,159,000 after buying an additional 441,318 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Travere Therapeutics by 79.2% in the first quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock valued at $1,423,000 after buying an additional 81,611 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Travere Therapeutics in the first quarter valued at about $452,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Travere Therapeutics in the fourth quarter valued at about $5,711,000.
Travere Therapeutics Stock Performance
Shares of NASDAQ TVTX opened at $9.24 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.75 and a debt-to-equity ratio of 5.10. The stock has a 50 day simple moving average of $8.30 and a 200-day simple moving average of $7.77. The company has a market cap of $703.44 million, a PE ratio of -4.40 and a beta of 0.77. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $16.79.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on TVTX shares. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Travere Therapeutics in a report on Tuesday, May 7th. Wedbush reissued an “outperform” rating and issued a $13.00 price objective on shares of Travere Therapeutics in a report on Wednesday, April 17th. Finally, Canaccord Genuity Group boosted their price objective on Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $14.64.
Check Out Our Latest Research Report on TVTX
Travere Therapeutics Company Profile
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
See Also
- Five stocks we like better than Travere Therapeutics
- What is a Dividend King?
- T-Mobile Stock Poised to Outperform Peers with Stellar Quarter
- Investing in Commodities: What Are They? How to Invest in Them
- Defense Stocks Soar to New Highs; Higher Highs Are Coming
- Investing in the High PE Growth Stocks
- Generac Raises Guidance: Why Is the Stock Still a Hold?
Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report).
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.